GlobalRPh Renal Dosing Masterv6.6
GlobalRPh source record

Canagliflozin - source Invokana/Invokamet statement

Local official-label summaryBase record retrieved 2026-09-05See the evidence for this drug3 sources available - open source summaries, references and comparisons
READ THE SOURCE-SPECIFIC ANSWER

Renal guidance at a glance

Confirm the product, indication and renal measure. The selected summary is not a complete prescribing monograph.

Choose a source to read (3)

Display order is not a clinical ranking. Date of retrieval is not the label revision date. Sources are never merged into one regimen. Other sources and conflicts remain below.

Official source

INVOKANA (canagliflozin) tablets

Product / population
Adult oral single agent. Does not apply to INVOKAMET or INVOKAMET XR.
Renal measure
Not specified; verify before use

Usual dosing and renal adjustment

Start 100 mg once daily before the first meal. For additional glycemic control, patients tolerating 100 mg with eGFR >=60 mL/min/1.73 m2 may increase to 300 mg daily. At eGFR 30 to <60, the usual maximum is 100 mg daily. Below 30, initiation is not recommended; adults already taking it with albuminuria >300 mg/day may continue 100 mg for the labeled renal/cardiovascular benefit.

Interaction-specific exception

With a UGT inducer, the label permits an increase from tolerated 100 mg to 200 mg daily; the maximum is 300 mg at eGFR >=60 and 200 mg below 60. This is a distinct interaction regimen, not the ordinary renal table.

Procedure interruption

Withhold at least 3 days before surgery or prolonged fasting when possible; resume when clinically stable and eating.

Source revision: | Retrieved: 2026-09-05. Retrieval date is not the revision date.

Source: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3

Scope: Source-read local summary; source-specific recommendations are not automatically interchangeable. GlobalRPh v6.6.

Full source card / provenance

All sources, comparison tools and evidence navigation
Source-first renal review

Evidence sources and renal implications

Choose a source to jump directly to its locally stored result. Qualitative precautions and evidence gaps remain visible even when no numerical clearance schedule is supplied.

Preserved GlobalRPh source

Preserved original GlobalRPh source

Preserved historical content; not revalidated as current prescribing guidance.

Renal method: Read the measure and population stated in the original source sections.
Retrieved: 2026-09-05

Read local renal resultOpen original reference
Handbook

Renal Drug Handbook, fifth edition

Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: See source.
Retrieved: 2026-09-05

Read local renal result

Source presence is not independent validation. A label mirror is not a second independent source; review the original reference and exact formulation.

Find text within this drug
Find a term without leaving this drug

Search the stored clinical text

Locate a word or phrase within this drug's source summaries. Choose all sources or one source to focus the search. The selection never hides warnings or source text, changes a dose, or proves that a renal finding is absent.

Find:

Enter at least two characters. Searches stay on this page and are not saved or sent.

All source summaries, original wording and provenance
Before applying a renal protocol

Check the setting. Compare whole sources.

No patient-specific dose is calculated. Context choices only display reminders; they do not validate, hide or change any regimen.

Share a reproducible source review

Choose sources below, then open a print-ready comparison with product scope, renal method, dates and cautions. Links can pin the exact local cards; they never contain patient values or choose a dose.

Open / share selected sources
Jump to renal guidanceClinician guide

Select two distinct source versions. The complete stored summaries will appear below.

Build a source-review outline for documentation

This creates a blank decision outline with the source identities you select, not a dose recommendation or completed clinical assessment. No patient fields are collected, saved or sent. Complete the clinical decisions in your approved documentation system.

Choose one or two sources above or use the source checkboxes below.

Renal-context checklist: population, kidney trend and dialysis

These prompts are a reading aid, not a prescription checklist or proof that all requirements have been met. No selections are stored or sent to a server.

Read the exact source scope, renal metric and date before selecting a row. No applicability assessment has been performed.

See source-specific renal methods and the clinical interpretation guide for the supporting context.

Go directly to the relevant source section

Renal dosing and precautions

Choose a source, then jump to its renal or dialysis section. These links locate stored text; they do not merge regimens or certify that sources agree.

Handbook source

Renal Drug Handbook, fifth edition

Historical 2019 reference; renal bands retain the book's own method labels.

Method: Not stated in selected source.

Read this complete source summary

No dialysis or renal heading shown? Read the complete source summary. Absence of a heading is not evidence that dose adjustment is unnecessary.

Compare or copy source versions

All content below is stored locally. Read a whole source version; do not combine its dose with another source's interval, renal metric or dialysis assumptions.

Original content / product scopeINVOKANA (canagliflozin) tabletsRenal Drug Handbook, fifth edition
Choose two source checkboxes below.
Historical source content is not a current prescription. Original GlobalRPh recommendations are preserved, not automatically certified as current. Product-label and professional additions below are separately attributed. Confirm indication, population, kidney-function method, monitoring and the full prescribing information before applying a regimen.

Important source distinctions

Product mismatch in the original source: the heading says INVOKANA but the body describes INVOKAMET. The complete original statement is preserved; do not apply its combination-product instructions to single-agent canagliflozin.

Locally stored source content

Original GlobalRPh protocol

Clinical facts and comments transcribed into a structured reading format. This is not a byte-for-byte HTML archive. Original source: https://globalrph.com/renal/medications-with-general-renal-dosing-statements/

GlobalRPh general renal statement

Canagliflozin - INVOKANA: Recommended Dosage for Patients with Renal Impairment: Assess renal function before initiating INVOKAMET and periodically thereafter. Do not initiate or continue INVOKAMET in patients with serum creatinine levels greater than or equal to 1.5 mg/dL for males or 1.4 mg/dL for females.

In patients who meet these serum creatinine levels, do not initiate or continue INVOKAMET if eGFR is persistently less than 45 mL/min/1.73 m2. No dose adjustment of INVOKAMET is needed in patients with mild renal impairment (eGFR of 60 mL/min/1.73 m2 or greater). Limit the dose of INVOKAMET to canagliflozin 50 mg twice daily in patients with moderate renal impairment with an eGFR of 45 to less than 60 mL/min/1.73 m2.

GRPH-general-canagliflozin-01 · Source section: GlobalRPh general renal statementRenal section finder
Separate U.S. product-label layer

FDA / DailyMed dosing and renal information

Official

INVOKANA (canagliflozin) tablets

Open original reference

Open / share this exact local source

NIH/NLM DailyMed - U.S. prescribing information · Adult oral single agent. Does not apply to INVOKAMET or INVOKAMET XR.

Renal method: Not specified in this summary.
Source date:
Retrieved: 2026-09-05

Source-read local summary; source-specific recommendations are not automatically interchangeable.

Usual dosing and renal adjustment

Start 100 mg once daily before the first meal. For additional glycemic control, patients tolerating 100 mg with eGFR >=60 mL/min/1.73 m2 may increase to 300 mg daily. At eGFR 30 to <60, the usual maximum is 100 mg daily. Below 30, initiation is not recommended; adults already taking it with albuminuria >300 mg/day may continue 100 mg for the labeled renal/cardiovascular benefit.

general-canagliflozin:dm-b9057d3b-b104-4f09-8a61-c61ef9d4a3f3-1 · Source locator: 2.2-2.3, Table 1

Interaction-specific exception

With a UGT inducer, the label permits an increase from tolerated 100 mg to 200 mg daily; the maximum is 300 mg at eGFR >=60 and 200 mg below 60. This is a distinct interaction regimen, not the ordinary renal table.

general-canagliflozin:dm-b9057d3b-b104-4f09-8a61-c61ef9d4a3f3-2 · Source locator: 2.4

Procedure interruption

Withhold at least 3 days before surgery or prolonged fasting when possible; resume when clinically stable and eating.

general-canagliflozin:dm-b9057d3b-b104-4f09-8a61-c61ef9d4a3f3-3 · Source locator: 2.5

Source identity and provenance
Source
https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=b9057d3b-b104-4f09-8a61-c61ef9d4a3f3
Retrieved
2026-09-05
Exact label title
INVOKANA (canagliflozin) tablets
DailyMed Set ID
b9057d3b-b104-4f09-8a61-c61ef9d4a3f3
Labeler
Janssen Pharmaceuticals, Inc.
DailyMed page updated
2026-06-11
FDA application
New Drug Application
U.S. product identity basis
Exact named product and route appear in the selected U.S. prescription label; current retail availability was not independently assessed.
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
ee69802d2cb64ae5e542a0ffdf7bd54902541fd5349853c6799e693e454deb3e
Separate handbook layer

Renal Drug Handbook cross-check

Handbook

Renal Drug Handbook, fifth edition

Open / share this exact local source

UK Renal Pharmacy Group / Ashley and Dunleavy / CRC Press · Historical 2019 reference; renal bands retain the book's own method labels.

Renal method: Not specified in this summary.
Source date: Not established
Retrieved: 2026-09-05

Historical handbook facts locally summarized; not a current U.S. label or a modern CRRT protocol.

Historical single-agent canagliflozin

The handbook retains normal dosing above GFR 60, limits established treatment to 100 mg daily in the 45-60 range, and advises against initiation below eGFR 60 and use below 45. It advises avoidance during the listed replacement modalities and describes canagliflozin as not dialysed. These older cutoffs do not replace the current INVOKANA label.

general-canagliflozin:rdh5-161-1 · Source locator: Renal impairment; renal replacement; Other information

Source-specific limits

This cross-check is for single-agent canagliflozin, not the mixed INVOKANA/INVOKAMET original statement.

Source identity and provenance
Retrieved
2026-09-05
Handbook page
Printed page 161; PDF page 180
Hash meaning
Locally authored source summary, not original SPL/XML/PDF bytes
Local summary SHA-256
d5fa508e1fd965b386c5d9045ed40def902ec160dc38cdbd5e86ec2b2247c497

Provenance and preservation

Additional summaries stored on this page: 1 official-label, 0 RX List, 0 professional, 1 handbook. Empty additional-source groups are not shown. A missing layer is not a no-adjustment recommendation.

Original source
https://globalrph.com/renal/medications-with-general-renal-dosing-statements/
Source retrieval
2026-09-05. This is not the source publication or label revision date.
Original source type
globalrph general · Numbered general entry 5
Local text SHA-256
b3818a39dddd6a7a7227ff2a020937554389d5f29215023a2ba1117901369286
Import versus clinical validation
Source-section locators identify where retained content came from. A source-section identifier does not assert that every numeric statement has been independently corroborated. The local text hash is not a hash of original HTML, an FDA PDF or SPL XML.

The original individual GlobalRPh pages commonly cite NIH/NLM DailyMed and instruct readers to review the applicable package insert for updates. That historical reference is preserved as context; it is not counted as an independently retrieved current label.

Read the full coverage report